熱門資訊> 正文
Achilles Therapeutics GAAP EPS—0.46美元错过0.32美元
2024-04-05 00:31
- Achilles Therapeutics press release (NASDAQ:ACHL): Q4 GAAP EPS of -$0.46 misses by $0.32.
- Cash and cash equivalents were $131.5 million as of December 31, 2023, as compared to $173.3 million as of December 31, 2022.
More on Achilles Therapeutics
- Seeking Alpha’s Quant Rating on Achilles Therapeutics
- Historical earnings data for Achilles Therapeutics
- Financial information for Achilles Therapeutics
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
